Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate.
Dadush
Oshrat
O
Pediatric Neuromuscular Laboratory and Neuropediatric Unit, Hadassah - Hebrew University Medical Center, Mount Scopus, P.O.B. 24035, Jerusalem 91240, Israel.
Aga-Mizrachi
Shlomit
S
Ettinger
Keren
K
Tabakman
Rinat
R
Elbaz
Moran
M
Fellig
Yakov
Y
Yanay
Nurit
N
Nevo
Yoram
Y
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D005353:Fibronectins / Q000235:genetics; D005355:Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D000068717:Glatiramer Acetate; D006614:Hindlimb / Q000187:drug effects / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007797:Laminin / Q000235:genetics*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D024510:Muscle Development / Q000187:drug effects / Q000235:genetics; D053580:Muscle Strength / Q000187:drug effects / Q000235:genetics; D018908:Muscle Weakness / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D009137:Muscular Dystrophy, Animal / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D017570:MyoD Protein / Q000235:genetics; D018008:Myogenin / Q000235:genetics; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D012038:Regeneration / Q000187:drug effects / Q000235:genetics; D014746:Vimentin / Q000235:genetics
D005353:Fibronectins; D007166:Immunosuppressive Agents; D007797:Laminin; D017570:MyoD Protein; C057363:MyoD1 myogenic differentiation protein; D018008:Myogenin; D010455:Peptides; D014746:Vimentin; C102645:laminin alpha 2; D000068717:Glatiramer Acetate